公开(公告)号：WO2008076904A1

公开(公告)日：2008-06-26

申请号：PCT/US2007/087615

申请日：2007-12-14

Applicant: AILERON THERAPEUTICS, INC. ,  NASH, Huw, M.

Inventor： NASH, Huw, M.

IPC: C07K5/12

CPC classification number: A61K38/12 ,  C07K1/1133 ,  C07K14/4747 ,  C07K14/68 ,  C07K14/705

Abstract: The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.

Abstract translation: 本发明提供新颖的拟肽大环化合物及其制备和使用的方法，以及氨基酸类似物和大环化合物形成接头以及可用于其生产的试剂盒。

公开(公告)号：WO2006048449A3

公开(公告)日：2006-10-19

申请号：PCT/EP2005055758

申请日：2005-11-04

Applicant: NOVO NORDISK AS ,  SENSFUSS ULRICH ,  CONDE FRIEBOES KILIAN WALDEMAR

Inventor： SENSFUSS ULRICH ,  CONDE FRIEBOES KILIAN WALDEMAR

IPC: C07K14/68 ,  A61K38/34

CPC classification number: C07K14/68

Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.

Abstract translation: 本发明涉及有效调节一种或多种黑皮质素受体类型的新型肽化合物，治疗中化合物的用途，包括向有需要的患者施用化合物的治疗方法，以及使用 药物制造中的化合物。 本发明的化合物在治疗肥胖以及与肥胖相关的各种疾病或病症方面特别有意义。

公开(公告)号：WO2005030797A2

公开(公告)日：2005-04-07

申请号：PCT/DK2004/000657

申请日：2004-09-29

Applicant: NOVO NORDISK A/S ,  CONDE-FRIEBOES, Kilian, Waldemar ,  SENSFUSS, Ulrich ,  MADSEN, Kjeld ,  JOHANSEN, Nils, Langeland ,  CHRISTENSEN, Leif ,  HANSEN, Thomas, Kruse ,  WULFF, Birgitte Schjellerup

Inventor： CONDE-FRIEBOES, Kilian, Waldemar ,  SENSFUSS, Ulrich ,  MADSEN, Kjeld ,  JOHANSEN, Nils, Langeland ,  CHRISTENSEN, Leif ,  HANSEN, Thomas, Kruse ,  WULFF, Birgitte Schjellerup

IPC: C07K7/00

CPC classification number: C07K14/68 ,  A61K38/00

Abstract: Small cyclic peptides of the formula X1-X2-X3-X4-X5-X6-X7-R 1 comprising 7-12 amino acid residues are provided. Said peptides are MC4 receptor agonists, and thus useful in the treatment of obesity and related diseases.

Abstract translation: 提供了包含7-12个氨基酸残基的式X1-X2-X3-X4-X5-X6-X7-R'的小环肽。 所述肽是MC4受体激动剂，因此可用于治疗肥胖症和相关疾病。

公开(公告)号：WO2004046166A2

公开(公告)日：2004-06-03

申请号：PCT/US2003/036396

申请日：2003-11-14

Applicant: ZENGEN, INC. ,  LIPTON, James, M.

Inventor： LIPTON, James, M.

IPC: C07K

CPC classification number: C07K14/68 ,  A61K38/00

Abstract: Novel peptides with antimicrobial activity are disclosed. The novel peptides are octomeric peptides modifiedfrom a-MSH. The modified a-MSH antimicrobial peptides disclosed herein may have enhanced activity against microbes over a-MSH due to modifications in peptide sequence and chirality of amino acids. Due an identified mechanism of action for antimicrobial activity in which cAMP accumulates in the microbial cell, it may be that microbes will not generate resistance to these modified a-MSH antimicrobial peptides.

Abstract translation: 公开了具有抗微生物活性的新型肽。 新型肽是由a-MSH修饰的八聚体肽。 由于肽序列的修饰和氨基酸的手性，本文公开的经修饰的a-MSH抗微生物肽可能具有比a-MSH更高的抗微生物活性。 由于cAMP在微生物细胞中积聚的抗菌活性的鉴定机制，微生物不会对这些修饰的a-MSH抗微生物肽产生抗性。

公开(公告)号：WO02064091A3

公开(公告)日：2003-03-13

申请号：PCT/US0204431

申请日：2002-02-13

Applicant: PALATIN TECHNOLOGIES INC ,  SHARMA SHUBH D ,  SHI YI-QUN ,  YANG WEI ,  CAI HUI-ZHI ,  SHADIACK ANNETTE

Inventor： SHARMA SHUBH D ,  SHI YI-QUN ,  YANG WEI ,  CAI HUI-ZHI ,  SHADIACK ANNETTE

IPC: A61K38/00 ,  A61P15/00 ,  C07K5/117 ,  C07K7/06 ,  C07K14/575 ,  C07K14/68 ,  A61K38/08

CPC classification number: C07K7/06 ,  A61K38/00 ,  C07K5/1024 ,  C07K14/575 ,  C07K14/68

Abstract: Metallopeptides are provided for use in treatment of sexual dysfunction in mammals. The metallopeptides are agonists for at least one of melanocortin-3 or melanocortin-4 receptors. The metallopeptides are conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion. Also provided are metallopeptides that are antagonists for at least one of melanocortin-3 or melanocortin-4 receptors.

Abstract translation: 金属肽被用于治疗哺乳动物的性功能障碍。 金属肽是黑皮质素-3或黑皮质素-4受体中的至少一种的激动剂。 金属肽在与金属离子的金属离子结合部分的络合作用下被构象地固定。 还提供了作为黑皮质素-3或黑皮质素-4受体中的至少一种的拮抗剂的金属肽。

公开(公告)号：WO0210195A3

公开(公告)日：2002-10-03

申请号：PCT/CA0101119

申请日：2001-08-02

Applicant: THERATECHNOLOGIES INC ,  GRAVEL DENIS ,  HABI ABDELKRIM ,  ABRIBAT THIERRY

Inventor： GRAVEL DENIS ,  HABI ABDELKRIM ,  ABRIBAT THIERRY

IPC: A61K38/00 ,  A61K38/04 ,  A61K38/22 ,  A61P3/10 ,  C07K7/08 ,  C07K7/23 ,  C07K14/00 ,  C07K14/47 ,  C07K14/55 ,  C07K14/575 ,  C07K14/58 ,  C07K14/585 ,  C07K14/595 ,  C07K14/60 ,  C07K14/605 ,  C07K14/635 ,  C07K14/65 ,  C07K14/655 ,  C07K14/665 ,  C07K14/675 ,  C07K14/68 ,  C07K14/695 ,  C07K14/78

CPC classification number: C07K14/6555 ,  A61K38/00 ,  C07K7/086 ,  C07K7/23 ,  C07K14/00 ,  C07K14/47 ,  C07K14/55 ,  C07K14/575 ,  C07K14/57509 ,  C07K14/57545 ,  C07K14/58 ,  C07K14/585 ,  C07K14/595 ,  C07K14/60 ,  C07K14/605 ,  C07K14/635 ,  C07K14/65 ,  C07K14/655 ,  C07K14/665 ,  C07K14/675 ,  C07K14/68 ,  C07K14/695 ,  C07K14/78

Abstract: The present invention is concerned with modified biological peptides providing increased potency, prolonged activity and/or increased half-life thereof. The modification is made via coupling through an amide bond with at least one conformationally rigid substituent, either at the N-terminal of the peptide, the C-terminal of the peptide, on a free amino or carboxyl group along the peptide chain, or at a plurality of these sites. Those peptides exhibit clinical usefulness for example in treating states of insulin resistance associated with pathologies such as type II diabetes.

Abstract translation: 本发明涉及改进的生物肽，其提供增加的效力，延长的活性和/或增加其半衰期。 通过酰胺键与至少一个构象刚性取代基，在肽的N-末端，肽的C-末端，沿着肽链的游离氨基或羧基上，或者在 多个这些网站。 这些肽表现出临床有用性，例如在治疗与II型糖尿病等病理相关的胰岛素抵抗状态下。

公开(公告)号：WO1996030504A1

公开(公告)日：1996-10-03

申请号：PCT/US1996003908

申请日：1996-03-22

Applicant: GENETIC THERAPY, INC. ,  UNIVERSITY OF SOUTHERN CALIFORNIA ,  ANDERSON, W., French ,  ZHAO, Yi ,  CHIANG, Yawen, L. ,  MACKRELL, Albert, J., Jr. ,  JANUSZESKI, Michael

Inventor： GENETIC THERAPY, INC. ,  UNIVERSITY OF SOUTHERN CALIFORNIA

IPC: C12N15/00

CPC classification number: C12N15/86 ,  A61K48/00 ,  C07K14/68 ,  C07K16/32 ,  C07K2319/00 ,  C12N2740/13043 ,  C12N2740/13045 ,  C12N2810/6054 ,  C12N2810/80 ,  C12N2810/851 ,  C12N2810/852 ,  C12N2810/854 ,  C12N2810/859

Abstract: A retroviral vector particle having a modified envelope polypeptide wherein a portion of the receptor binding region of the envelope is replaced with a targeting polypeptide which binds to a ligand or a receptor on the targeted cells. The targeting polypeptide may be a single chain antibody. Such retroviral vector particles are useful in delivering genes encoding therapeutic agents to desired target cells or tissues in vivo.

Abstract translation: 具有修饰的包膜多肽的逆转录病毒载体颗粒，其中外壳的受体结合区的一部分被与靶细胞上的配体或受体结合的靶向多肽所取代。 靶向多肽可以是单链抗体。 这样的逆转录病毒载体颗粒可用于将体内编码治疗剂的基因递送至所需的靶细胞或组织。

公开(公告)号：WO1995013086A1

公开(公告)日：1995-05-18

申请号：PCT/US1994012897

申请日：1994-11-09

Applicant: HOUGHTEN PHARMACEUTICALS, INC.

Inventor： HOUGHTEN PHARMACEUTICALS, INC. ,  SUTO, Mark, J. ,  GIRTEN, Beverly, E. ,  HOUGHTEN, Richard, A. ,  LOULLIS, Costas, C. ,  TUTTLE, Ronald, R.

IPC: A61K38/00

CPC classification number: A61K38/08 ,  C07K5/1024 ,  C07K14/68 ,  C07K14/685 ,  C07K14/695

Abstract: The present invention provides novel cytokine restraining agents, which limit or control the biological activity of cytokines. The invention also provides pharmaceutical compositions comprising a cytokine restraining peptide and methods of administering the pharmaceutical composition to a subject. The invention further provides methods for using the novel peptides to restrain cytokine activity in a subject.

Abstract translation: 本发明提供限制或控制细胞因子生物学活性的新型细胞因子抑制剂。 本发明还提供了包含细胞因子抑制肽的药物组合物和向受试者施用药物组合物的方法。 本发明进一步提供了使用新型肽抑制受试者中细胞因子活性的方法。

公开(公告)号：WO2015191765A2

公开(公告)日：2015-12-17

申请号：PCT/US2015/035180

申请日：2015-06-10

Applicant: THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA

Inventor： CAI, Minying ,  HRUBY, Victor, J.

IPC: C12Q1/68

CPC classification number: C07K14/68 ,  C07K14/685

公开(公告)号：WO2012158960A2

公开(公告)日：2012-11-22

申请号：PCT/US2012038425

申请日：2012-05-17

Applicant: H LEE MOFFITT CANCER CT & RES ,  INTEZYNE TECHNOLOGIES INC ,  UNIV ARIZONA STATE ,  UNIV TEXAS ,  GILLIES ROBERT J ,  MORSE DAVID L ,  BARKEY NATALIE M ,  SILL KEVIN N ,  VAGNER JOSEF ,  TAFRESHI NARGES K ,  SESSLER JONATHAN L ,  PREIHS CHRISTIAN

Inventor： GILLIES ROBERT J ,  MORSE DAVID L ,  BARKEY NATALIE M ,  SILL KEVIN N ,  VAGNER JOSEF ,  TAFRESHI NARGES K ,  SESSLER JONATHAN L ,  PREIHS CHRISTIAN

CPC classification number: C07K5/1024 ,  A61K38/34 ,  A61K47/48246 ,  A61K47/488 ,  A61K47/64 ,  A61K47/6907 ,  A61K49/0056 ,  A61K49/101 ,  A61K49/1809 ,  C07K7/08 ,  C07K14/68 ,  C07K14/723

Abstract: The subject invention pertains to a modified MCIR peptide ligand comprising a peptide that is a melanocortin 1 receptor (MCIR) ligand and a functionality or linker, such as a click functionality, for conjugation to a surface or agent. The modified MCIR peptide ligand can be coupled, e.g., via a click reaction with a complementary click functionality attached, to a moiety to form an MClR-targeted agent. Drugs, contrast agents, polymers, particles, micelles, surfaces of larger structures, or other moieties can be targeted to the MCIR. The subject invention also pertains to a MCIR peptide ligand-micelle complex comprising a peptide that is a melanocortin 1 receptor ligand connected via a click reaction product to a micelle. The micelle is stable in vivo and can target melanoma tumor cells by association of the peptide ligand with the MCIR or the tumor and selectively provide a detectable and/or therapeutic agent (such as an imageable contrast agent and/or anti-cancer agent) selectively to the tumor cell.

Abstract translation: 本发明涉及包含黑色素皮质素1受体（MCIR）配体的肽和功能性或接头，例如用于与表面或试剂缀合的点击功能的修饰的MCIR肽配体。 修饰的MCIR肽配体可以例如通过与附加的互补点击功能的点击反应偶联到部分上以形成MClR靶向试剂。 药物，造影剂，聚合物，颗粒，胶束，较大结构的表面或其它部分可以靶向MCIR。 本发明还涉及包含通过点胶反应产物与胶束连接的黑皮质素1受体配体的肽的MCIR肽配体 - 胶束复合物。 胶束在体内是稳定的并且可以通过肽配体与MCIR或肿瘤的缔合来靶向黑素瘤肿瘤细胞，并选择性地提供可检测和/或治疗剂（例如可成像的造影剂和/或抗癌剂） 到肿瘤细胞。